Monetary benefits will outweigh the hassle of batch record harmonization, says Siegfried Schmitt, principal consultant at PAREXEL.
Q: Our company recently acquired several new production sites in Europe, Asia, and the Americas. As part of the integration process, we decided to harmonize our batch records. We appreciate that local regulations and differences regarding the type of production equipment we use may require some local adaptations and deviations from a standard template; however, we are faced with stiff opposition from many sites to change their batch record design. Can you advise on how best to convince everyone of the benefits of a harmonized template?
A: The integration you describe will without doubt require many changes to the documentation, and therefore, it is a sensible decision to think about harmonizing documents, such as batch records. You are correct that there will be differences in the equipment and the processes, even for the same product by the same synthetic method, but in different facilities. But, this in itself is not an impediment to creating a universal batch record template.
It is important to consider why batch record templates differ so widely. First, the workforce will be used to different styles of documentation. How much or how little detail do they require to perform a task? It is not unusual to find a 10-page document used for a process in one location to extend to 50 pages for the exact same process elsewhere.
Next, let us look at the style of the contents: Is it all text? Is there use of pictures or graphics? Is it all in a logical sequence? Is it in one language or in multiple languages? Does it require each page to be signed by five persons for each batch record, or is there just one signature page? All these styles exist, and they all are developed for specific reasons. It is thus important to understand these reasons in order to design a universally accepted template.
Having the opportunity to completely redesign the batch record template provides a unique chance to build in as many safeguards from a data integrity perspective as possible. This includes removing any ambiguity regarding what must be recorded, by who, when, and how. For example, the instruction ‘add 100 liters 10% NaOH over 1 hour should have fields for entering the actual values that should look like this:
This technique makes it clear to the operators what fields to complete and how to enter the values correctly. The use of symbols and colors is encouraged (e.g., to highlight critical steps, warn of potentially dangerous substances, etc.).
This is also a superb opportunity to eliminate the ‘numeritis disease’ (i.e., the unnecessary and time-wasting use of highly complex numbering systems). Step 001 in the batch record should be followed by step 002, then step 003, etc. There is no need at all for having something like step 1.2.5.2.8a.
Depending on the level of automation in the plants, you may be able to move from paper batch records to electronic batch records. The latter will provide a higher degree of data integrity as much fewer manual entries of data will be required. Thus, the standardization of the batch record can indirectly also drive standardization of the computerized systems in your plants.
Now let us look at some indisputable benefits of having a standard batch record template rather than a free-for-all:
Every day a product can be released to the market earlier because of any of the above benefits can result in monetary benefits. And who is to dispute that advantage in your company?
In summary, if the regulatory compliance benefits of a standardized batch record template aren’t compelling enough, monetary benefits gained by earlier release of drug product will no doubt make it a straightforward decision.
Pharmaceutical Technology
Vol. 42, No. 5
May 2018
Pages: 66
When referring to this article, please cite it as S. Schmitt, "Harmonization of Batch Records" Pharmaceutical Technology 42 (5) 2018.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.